Unknown

Dataset Information

0

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.


ABSTRACT: This study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone.Systematic literature reviews were performed to identify studies directly comparing SAXA+MET versus ACAR+MET, and to obtain diabetes-related events costs which were modified by hospital surveys. A Cardiff Diabetes Model was used to estimate the long-term economic and health treatment consequences in patients with T2DM. Costs (2014 Chinese yuan) were calculated from the payer's perspective and estimated over a patient's lifetime.SAXA+MET predicted lower incidences of most cardiovascular events, hypoglycemia events and fatal events, and decreased total costs compared with ACAR+MET. For an individual patient, the quality-adjusted life-years (QALYs) gained with SAXA+MET was 0.48 more than ACAR+MET at a cost saving of ¥18,736, which resulted in a cost saving of ¥38,640 per QALY gained for SAXA+MET versus ACAR+MET. Results were robust across various univariate and probabilistic sensitivity analyses.SAXA+MET is a cost-effective treatment alternative compared with ACAR+MET for patients with T2DM in China, with a little QALYs gain and lower costs. SAXA is an effective, well-tolerated drug with a low incidence of adverse events and ease of administration; it is anticipated to be an effective second-line therapy for T2DM treatment.

SUBMITTER: Gu S 

PROVIDER: S-EPMC5119856 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.

Gu Shuyan S   Zeng Yuhang Y   Yu Demin D   Hu Xiaoqian X   Dong Hengjin H  

PloS one 20161122 11


<h4>Objective</h4>This study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone.<h4>Methods</h4>Systematic literature reviews were performed to identify studies directly comparing SAXA+MET versus ACAR+MET, and to obtain diabetes-related events costs which were modified by hospital surveys. A Cardiff Diabetes Model was used to estimate the l  ...[more]

Similar Datasets

| S-EPMC5091768 | biostudies-literature
| S-EPMC8111283 | biostudies-literature
| S-EPMC9305296 | biostudies-literature
| S-EPMC8506708 | biostudies-literature
| S-EPMC7898389 | biostudies-literature
| S-EPMC7816108 | biostudies-literature
| S-EPMC3216433 | biostudies-literature
| S-EPMC7205241 | biostudies-literature
| S-EPMC4807816 | biostudies-literature
| S-EPMC10499965 | biostudies-literature